MediciNova, Inc.

TSE:4875 Stock Report

Market Cap: JP¥14.9b

MediciNova Valuation

Is 4875 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4875 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4875's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4875's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4875?

Key metric: As 4875 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 4875. This is calculated by dividing 4875's market cap by their current book value.
What is 4875's PB Ratio?
PB Ratio1.8x
BookUS$55.07m
Market CapUS$98.58m

Price to Book Ratio vs Peers

How does 4875's PB Ratio compare to its peers?

The above table shows the PB ratio for 4875 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.6x
4588 Oncolys BioPharma
7.9xn/aJP¥15.5b
4883 Modalis Therapeutics
3.1xn/aJP¥8.8b
190A Chordia Therapeutics
4.6xn/aJP¥20.0b
4884 Kringle Pharma
2.8xn/aJP¥6.1b
4875 MediciNova
1.8x-6.1%JP¥98.6m

Price-To-Book vs Peers: 4875 is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (4.6x).

Price to Book Ratio vs Industry

How does 4875's PB Ratio compare vs other companies in the JP Biotechs Industry?

1 CompanyPrice / BookEstimated GrowthMarket Cap
2342 Transgenic Group
0.6xn/aUS$22.18m
No more companies available in this PB range
4875 1.8xIndustry Avg. 3.5xNo. of Companies4PB02.44.87.29.612+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 4875 is good value based on its Price-To-Book Ratio (1.8x) compared to the JP Biotechs industry average (3.5x).

Price to Book Ratio vs Fair Ratio

What is 4875's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4875 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 4875's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4875 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥298.00
JP¥1,233.17
+313.8%
25.0%JP¥1,541.46JP¥924.88n/a2
Nov ’25JP¥252.00
JP¥1,149.80
+356.3%
25.0%JP¥1,437.25JP¥862.35n/a2
Oct ’25JP¥302.00
JP¥1,149.80
+280.7%
25.0%JP¥1,437.25JP¥862.35n/a2
Aug ’25JP¥200.00
JP¥2,476.50
+1,138.2%
62.5%JP¥4,024.31JP¥928.69n/a2
Jul ’25JP¥231.00
JP¥2,476.50
+972.1%
62.5%JP¥4,024.31JP¥928.69n/a2
Jun ’25JP¥218.00
JP¥2,548.56
+1,069.1%
64.7%JP¥4,197.62JP¥899.49n/a2
May ’25JP¥205.00
JP¥2,548.56
+1,143.2%
64.7%JP¥4,197.62JP¥899.49n/a2
Apr ’25JP¥218.00
JP¥2,548.56
+1,069.1%
64.7%JP¥4,197.62JP¥899.49n/a2
Mar ’25JP¥196.00
JP¥2,548.56
+1,200.3%
64.7%JP¥4,197.62JP¥899.49n/a2
Feb ’25JP¥207.00
JP¥2,452.31
+1,084.7%
63.6%JP¥4,012.88JP¥891.75n/a2
Jan ’25JP¥210.00
JP¥2,452.31
+1,067.8%
63.6%JP¥4,012.88JP¥891.75n/a2
Dec ’24JP¥264.00
JP¥2,452.31
+828.9%
63.6%JP¥4,012.88JP¥891.75n/a2
Nov ’24JP¥291.00
JP¥2,465.78
+747.3%
63.6%JP¥4,034.91JP¥896.65JP¥252.002
Oct ’24JP¥310.00
JP¥2,465.78
+695.4%
63.6%JP¥4,034.91JP¥896.65JP¥302.002
Sep ’24JP¥350.00
JP¥2,317.95
+562.3%
62.5%JP¥3,766.67JP¥869.23JP¥239.002
Jun ’24JP¥307.00
JP¥2,271.65
+640.0%
63.6%JP¥3,717.25JP¥826.06JP¥218.002
May ’24JP¥291.00
JP¥2,271.65
+680.6%
63.6%JP¥3,717.25JP¥826.06JP¥205.002
Apr ’24JP¥289.00
JP¥2,271.65
+686.0%
63.6%JP¥3,717.25JP¥826.06JP¥218.002
Mar ’24JP¥305.00
JP¥2,271.65
+644.8%
63.6%JP¥3,717.25JP¥826.06JP¥196.002
Feb ’24JP¥309.00
JP¥2,271.65
+635.2%
63.6%JP¥3,717.25JP¥826.06JP¥207.002
Jan ’24JP¥308.00
JP¥2,271.65
+637.6%
63.6%JP¥3,717.25JP¥826.06JP¥210.002
Dec ’23JP¥387.00
JP¥2,329.93
+502.0%
63.6%JP¥3,812.62JP¥847.25JP¥264.002
Nov ’23JP¥306.00
JP¥1,774.67
+480.0%
76.1%JP¥3,685.85JP¥819.08JP¥291.003

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,128.50

7D

3.4%

1Y

-8.5%

Tsumura

JP¥364.3b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,844.00

7D

0.4%

1Y

73.3%

ASKA Pharmaceutical HoldingsLtd

JP¥57.2b

Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.

4886

JP¥2,031.00

7D

-0.2%

1Y

11.5%